Gentamycine B. Braun 1 mg/ml solution pour perfusionAmoclaneEG 875 mg/125 mg FilmtablettenAmoxicillin AB 1000 mg dispergeerbare tablettenCefazoline Sandoz 1 g poeder voor oplossing voor injectieFloxapenpoeder voor oplossing voor injectie 1 gEUSAPRIM Forte 160 mg/800 mg tablettenAvelox 400 mg FilmtablettenDelamoxyle 1 gpoudre pour solution injectable/pour perfusionCeftriaxone Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusieClindamycin Sandoz 300 mg harde capsulesRifadine 300 mg capsuleshardPenicilline 1.000.000 IEpoeder voor oplossing voor injectieLevofloxacine EG 500 mg comprimés pelliculés
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Primary: composite clinical success at 6 months, defined as the absence of all-cause mortality, unplanned cardiac surgery, embolic events, recurrent bacteremia
Endpoint detail
Patient-reported satisfaction at completion of oral treatment., Complications (including antibiotic-related adverse events, treatment interruption/modification, non-adherence), during the entire treatment course., PK/PD target attainment of oral antibiotics, assessed per agent, based on predefined PK/PD thresholds at two time point during treatment., Length and cost of hospital stay, calculated from admission to discharge., Total duration of antibiotic therapy, calculated from treatment initiation until the final antibiotic dose administered for the same endocarditis episode.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.